Varex Imaging Corp (VREX) · Aug 10, 2026 · Earnings

EPS beats sharply, but tariff refunds inflate the margin rebound

EPS beats sharply, but tariff refunds inflate the margin rebound

The quarter cleared expectations on EPS, but not on reported revenue. Non-GAAP diluted EPS was $0.31 versus a published consensus near $0.21–$0.22, a clear beat, while revenue of $210.5 million was below the roughly $215.5–$218.2 million expectation range. However, product sales before the $7 million customer-reimbursement accrual were approximately $217 million, making the underlying top line broadly in line with expectations. (Financial Highlights; Management commentary)

MetricQ3 FY2026Q3 FY2025 / expectationRead
Revenue$210.5M$203.0M; consensus roughly $215.5M–$218.2M4% reported growth, but below consensus (Financial Highlights)
Product sales before reimbursement accrual~$217M—Underlying sales roughly in line (Management commentary)
Non-GAAP diluted EPS$0.31$0.13; consensus roughly $0.21–$0.22Material beat (Non-GAAP net income reconciliation)
Non-GAAP gross margin36.7%33%–34% company guidance; 33.5% prior yearWell above both guidance and prior year (Non-GAAP reconciliation)
Adjusted EBITDA$33.1M$27.5M prior year20% year-over-year increase (Adjusted EBITDA reconciliation)
Operating cash flow$21M—Positive cash generation, but liquidity declined (Management commentary; Balance Sheet)

The margin beat is much less clean than the headline suggests. Varex received $17 million of tariff refunds and recorded a $7 million accrual for expected customer reimbursements, producing an estimated $10 million increase to gross profit. That benefit explains a substantial portion of the 36.7% non-GAAP gross margin and $24.5 million of non-GAAP operating income; excluding it, the underlying operating result would have been materially weaker. (Management commentary; Non-GAAP operating income reconciliation)

Industrial demand is doing the heavy lifting while Medical remains a drag. Industrial revenue rose to $76.5 million from $60.9 million, roughly 26% higher year over year, helped by cargo and vehicle inspection systems. Medical revenue fell to $134.0 million from $142.1 million, so the overall 4% revenue increase reflects a sharp mix shift rather than broad-based growth. (Financial Highlights)

The outlook is less informative because management withdrew guidance and the call. Varex did not provide fourth-quarter or full-year guidance and cancelled its earnings call because of the pending Teledyne transaction. Since the transaction was already announced, this is more a loss of forward visibility than a new operating deterioration; nevertheless, investors cannot test the quarter's momentum against updated targets. (Management commentary)

The net read is a modest beat with notable quality caveats. EPS substantially exceeded the published expectation and underlying product sales were near consensus, supporting a mildly positive read. But the earnings upside was helped by a non-recurring tariff refund, Medical revenue declined, cash fell to $99.2 million from $155.1 million at fiscal year-end, and inventory increased to $347.1 million from $299.4 million. (Balance Sheet; Management commentary)

Original filing on SEC EDGAR

More Varex Imaging Corp news

EPS beats sharply, but tariff refunds inflate the margin rebound | VREX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.